| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 19.9% | 0% | $7.75M | $1.1M | 10.6M | +16.6% | GILEAD SCIENCES, INC. | Jun 30, 2025 |
| Frazier Life Sciences Public Fund, L.P. | 9.9% | 0% | $5.94M | $1.75M | 8.14M | +41.7% | Frazier Life Sciences Public Fund, L.P. | Jun 30, 2025 |
| Point72 Asset Management, L.P. | 9.9% | +38.6% | $6.74M | $3.37M | 8M | +100% | Point72 Asset Management, L.P. | Sep 30, 2025 |
| Coastlands Capital LP | 9.99% | $3.74M | 5.35M | Coastlands Capital LP | Dec 4, 2025 | |||
| AbbVie Inc. | 9% | $3.3M | 4.35M | AbbVie Inc. | Feb 11, 2025 | |||
| STEMPOINT CAPITAL LP | 7.2% | $3.37M | 4M | StemPoint Capital LP | Sep 30, 2025 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Change | Price | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 22.1M | $18.6M | -$1.23M | $0.84 | 36 |
| 2025 Q2 | 23.8M | $16.2M | +$854K | $0.68 | 35 |
| 2025 Q1 | 22.5M | $16.3M | -$3.18M | $0.72 | 35 |
| 2024 Q4 | 25.8M | $24.7M | -$145K | $0.96 | 34 |
| 2024 Q3 | 15.9M | $12.5M | +$1.13M | $0.79 | 32 |
| 2024 Q2 | 13M | $12.3M | +$1.79M | $0.95 | 30 |
| 2024 Q1 | 11M | $11.9M | -$2.68M | $1.08 | 28 |
| 2023 Q4 | 15M | $8.22M | -$1.54M | $0.55 | 32 |
| 2023 Q3 | 15.9M | $33.5M | -$315K | $2.11 | 30 |
| 2023 Q2 | 16M | $41.9M | -$192K | $2.62 | 32 |
| 2023 Q1 | 16.1M | $51M | +$462K | $3.17 | 32 |
| 2022 Q4 | 15.9M | $42.8M | -$710K | $2.69 | 28 |
| 2022 Q3 | 16.6M | $48.3M | -$3.75M | $2.91 | 28 |
| 2022 Q2 | 17.9M | $52.2M | -$3.65M | $2.92 | 29 |
| 2022 Q1 | 18.8M | $133M | -$2.57M | $7.07 | 41 |
| 2021 Q4 | 18.3M | $269M | +$225M | $16.00 | 41 |